Saphris: What You Need to Know
How sublingual asenapine works, where it fits in schizophrenia and bipolar I disorder, how it compares with alternatives, and what its depression research suggests.

In this article
A medication can be effective and still need to fit your daily life. Saphris is unusual because it dissolves under the tongue, and its broad receptor activity creates both useful treatment effects and practical trade-offs. Understanding those details can make the conversation about benefits, side effects, and alternatives much more concrete.
What is Saphris (asenapine)?
Saphris is a sublingual second-generation antipsychotic. In the United States it is approved for adult schizophrenia, acute manic or mixed episodes of bipolar I disorder in adults and children aged 10–17, adjunctive treatment with lithium or valproate in adults, and adult bipolar I maintenance monotherapy. It is not approved for childhood schizophrenia or for MDD.1
These are different treatment roles. Treating mania, preventing another mood episode, and treating an acute depressive episode are not interchangeable goals.
An in-depth look at its mechanism of action
Asenapine is a multireceptor antagonist: it blocks activation at several dopamine, serotonin, adrenergic, and histamine receptors. Receptors are signaling targets, not simply containers for neurotransmitters. A medicine can change a circuit's response without removing the neurotransmitter from the brain.2
Dopamine D2 and serotonin 5-HT2A: central treatment targets
D2 and 5-HT2A antagonism are thought to contribute to asenapine's antipsychotic action. Blocking D2 signaling can reduce dopamine-mediated effects, while serotonin-receptor blockade modifies the overall signaling pattern. The complete route from receptor action to symptom improvement remains incompletely mapped.12
That is different from ‘correcting every chemical imbalance.’ Clinical response is measured through changes in symptoms and functioning. Receptor affinity explains what a medicine can engage; it does not establish that one person will benefit more than another.
Other serotonin and adrenergic receptors: a broader signaling profile
Asenapine also binds strongly to several other serotonin receptors, including 5-HT2C, 5-HT6, and 5-HT7, and to alpha-adrenergic receptors. In functional tests using cloned human receptors, it behaved as an antagonist at numerous targets, including 5-HT1A and alpha-2 receptors. Binding to 5-HT1A should therefore not automatically be described as partial agonism.2
This broad profile gives researchers reasons to explore effects beyond psychosis, including mood and cognition. Those possibilities are research questions, not a guaranteed antidepressant or cognitive-enhancing effect. Alpha-1 blockade also helps explain why blood pressure can fall on standing.12
Histamine and muscarinic receptors: connecting mechanism to trade-offs
Asenapine blocks H1 histamine receptors, which helps explain its tendency to cause sleepiness. Laboratory testing found much weaker affinity for muscarinic receptors. That corrects an important distinction: asenapine should not be described as having a strong muscarinic-blocking mechanism.2
A limited muscarinic effect does not mean dry mouth or other adverse effects cannot occur. Real-world tolerability depends on the whole medicine, dose, other treatments, and the person—not one receptor in isolation.7
Why dissolving under the tongue changes drug exposure
The route is part of how this formulation works. Under-the-tongue absorption allows much more asenapine to reach circulation than swallowing it. The label reports about 35% bioavailability after a 5 mg sublingual dose, compared with less than 2% when swallowed. Those figures describe drug exposure, not the percentage of symptom relief.1
Leave the tablet under the tongue to dissolve. Do not chew, crush, split, or swallow it as a conventional tablet, and do not eat or drink for 10 minutes afterward. Use dry hands and follow the peel-back package instructions.7
What is established in schizophrenia and bipolar disorder?
Saphris is an established option for adult schizophrenia and bipolar I manic or mixed episodes. For some people, the sublingual formulation is useful when swallowing conventional tablets is difficult; it still requires careful administration.17
Maintenance evidence is also important. In a randomized withdrawal study, adults who stabilized on asenapine were assigned to continue it or switch to placebo for 26 weeks. Time to recurrence of a mood episode was longer with continued asenapine. Because the trial selected people who had already responded and tolerated treatment, it speaks most directly to continuing a successful treatment—not to predicting everyone's first response.3
Could Saphris help with major depressive disorder (MDD)?
It is a reasonable research question, but MDD is not an approved Saphris indication. Its broad serotonin and adrenergic actions provide a pharmacological reason to investigate mood effects, while the clinical depression findings need to be read in the populations actually studied.12
An exploratory analysis of two short bipolar I mania/mixed-episode trials found greater reductions in depressive symptoms with asenapine than placebo in selected subgroups. That is an encouraging signal, but these were people having manic or mixed episodes—not a dedicated trial of unipolar MDD or an acute bipolar-depression trial.4
A small open-label PTSD pilot also reported improvement on a depression measure; many participants had co-occurring MDD. Eighteen people started and eleven completed 12 weeks. Because there was no placebo group and participants remained on antidepressants, the study cannot separate asenapine's effect from other influences or establish it as an MDD treatment.5
If a specialist considers an off-label trial, ask what symptom is being targeted, why Saphris fits better than better-studied alternatives, and how benefit will be reviewed. Aripiprazole and quetiapine XR, for example, have approved adult-MDD augmentation roles. Having options is hopeful; matching the option to the evidence and diagnosis makes that hope more useful.810
Potential pros
Reasons to discuss Saphris may include:
- An established option for mania and adult bipolar maintenance, as well as adult schizophrenia.13
- A dissolving-under-the-tongue formulation rather than a conventional swallowed tablet.7
- Less average weight gain than olanzapine in a one-year comparative trial, although weight and metabolic monitoring remain necessary.67
Potential cons
The practical downsides deserve equal attention:
- Usually twice-daily dosing, with a 10-minute eating/drinking pause after each dose.7
- Mouth numbness or altered taste, sleepiness, dizziness, weight gain, or uncomfortable restlessness.7
- Movement-related adverse effects remain possible; lower weight gain than a comparator does not mean lower risk in every category.6
- No approved MDD or acute bipolar-depression indication. A maintenance benefit does not establish effectiveness for a current depressive episode.13
Saphris versus other antipsychotics
These are differences to discuss, not a universal ranking. The olanzapine comparison below comes from a head-to-head trial; the other rows compare treatment indications and administration requirements rather than claiming head-to-head superiority.
| Compared with | Key distinction | What to consider |
|---|---|---|
| Olanzapine | In a one-year schizophrenia/schizoaffective-disorder trial, asenapine produced less average weight gain, but more extrapyramidal side effects.6 | This was not a universal efficacy win: completion rates and symptom-score changes favored olanzapine, with study-selection limitations. The lower weight burden is a trade-off, not proof Saphris is best overall.6 |
| Quetiapine XR | Both have bipolar-mania roles, but quetiapine XR also has approved bipolar-depression and adjunctive adult-MDD indications.110 | Saphris offers a sublingual option. Quetiapine XR is swallowed once daily; sedation and metabolic effects still deserve attention with either choice.710 |
| Aripiprazole | Aripiprazole has an approved role as an add-on to antidepressants for MDD; Saphris does not.18 | Aripiprazole tablets are generally once daily without regard to meals. Saphris is generally twice daily with an eating/drinking pause. Restlessness can occur with either.78 |
| Lurasidone | Lurasidone has an established bipolar I depression indication; Saphris has acute-mania and adult bipolar-maintenance indications.19 | Lurasidone needs at least 350 calories with each dose. Saphris needs under-the-tongue absorption and no food or drink for 10 minutes afterward. The episode being treated matters as much as convenience.79 |
Safety, interactions, and follow-up
Review weight, glucose, lipids, blood pressure, movement symptoms, and prolactin-related symptoms with your clinician. Report persistent inner restlessness, new involuntary movements, troublesome sedation, or mouth sores. Discuss pregnancy, breastfeeding, and other health conditions before treatment.17
Severe liver impairment is a contraindication. Fluvoxamine can increase exposure, and asenapine can increase paroxetine exposure. Other sedating medicines, alcohol, blood-pressure drugs, and QT-prolonging medicines also need review. Have a pharmacist check the complete list rather than assuming all combinations carry the same risk.1
Seek urgent care for facial or throat swelling, breathing or swallowing difficulty, a seizure, or fever with severe stiffness and confusion. Like other antipsychotics, asenapine carries a boxed warning about increased mortality in older adults with dementia-related psychosis and is not approved for that use.7
The takeaway
Saphris offers a distinct formulation and an established place in schizophrenia and bipolar I care. Its mechanism is broader than dopamine blockade alone, and its possible antidepressant effects remain an interesting research direction. A useful plan weighs the actual treatment target, daily administration, tolerability, and alternatives—and checks whether the benefit is making life more manageable.
Words worth knowing
Cognitive behavioral therapy (CBT)
A structured therapy that helps people notice patterns between thoughts, feelings, and actions, then practice more helpful responses.
References
- DailyMed. Saphris (asenapine) prescribing information. Updated January 2025: indications, pharmacology, absorption, warnings, and interactions.
- Shahid M, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology. 2009;23:65–73. Laboratory receptor research.
- Szegedi A, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with bipolar I disorder. American Journal of Psychiatry. 2018;175:71–79.
- Szegedi A, et al. Effects of asenapine on depressive symptoms during bipolar I manic or mixed episodes: exploratory post hoc analyses. BMC Psychiatry. 2011;11:101.
- Pilkinton P, et al. An open-label pilot study of adjunctive asenapine for PTSD. Psychopharmacology Bulletin. 2016;46:8–17. Not a dedicated controlled MDD trial.
- Schoemaker J, et al. Long-term assessment of asenapine versus olanzapine in schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138–146.
- MedlinePlus. Asenapine: patient instructions, precautions, and adverse effects.
- DailyMed. Abilify (aripiprazole) prescribing information: MDD augmentation and administration.
- Latuda (lurasidone) U.S. prescribing information: bipolar depression and food requirements.
- DailyMed. Seroquel XR (quetiapine) prescribing information: indications, administration, and safety.
